Skip to main content

Table 5 EORTC QLQ-LC13 and other symptom scores during first-line chemotherapy and during MT

From: Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting

 

1st Line

Maintenance

    
 

Mean

95% CI

Mean

95% CI

Diff.

95% CI

F-value

p-value

Dyspnoea

23.0

19.9-26.0

21.2

0.0-45.4

1.73

−22.6-26.1

0.230

0.632

Coughing

31.1

27.8-34.4

26.7

21.4-32.0

4.4

−1.8-10.6

1.943

0.165

Haemoptysis

2.8

1.1-4.5

<0.1

0.0-10.5

2.8

−7.8-13.4

0.273

0.603

Sore mouth

8.0

5.5-10.4

7.0

2.9-11.1

1.0

−3.7-5.8

0.183

0.670

Dysphagia

9.1

6.8-11.4

6.1

1.7-10.6

3.0

−2.0-8.0

1.408

0.237

Peripheral neuropathy

14.9

11.8-18.0

18.8

13.7-23.9

−3.9

−9.9-2.0

1.711

0.192

Alopecia

10.2

7.3-13.0

21.7

16.6-26.8

−11.5

−17.4- -5.7

15.116

<0.001

Pain in chest

13.2

10.8-15.7

8.0

4.3-11.7

5.3

0.8-9.7

5.437

0.022

Pain in arm or shoulder

18.1

14.8-21.3

19.6

14.6-24.7

−1.6

−7.6-4.4

0.266

0.607

Pain in other parts

24.9

21.0-28.9

25.2

18.3-32.0

−0.2

−8.1-7.6

0.004

0.951

Taste Alterationsa

19.7

16.1-23.2

31.4

24.3-38.4

−11.7

−19.6- -3.7

8.442

0.004

Skin Toxicitya

18.1

15.0-21.3

16.9

12.0-21.8

1.2

−4.6-7.0

0.179

0.673

  1. 95% CI 95% confidence interval; Bold type indicates p <.05
  2. aitems from the EORTC item bank
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us